Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period

Bone Marrow Transplantation volume 42, pages 145–157 (2008)Cite this article

Abstract

Allogeneic SCT is important in myelodysplastic syndrome, the BCR-ABL-negative chronic myeloproliferative diseases (CMPDs) and in poor-risk AML. Techniques to monitor the minimal residual disease, for example, by PCR or immunophenotyping gain increasing importance in the post transplantation period as basis for improved and earlier therapeutic interventions in impending relapse. Recent markers such as the NPM1 mutations in AML or the JAK2V617F mutation in the CMPD can be exactly quantified by real-time PCR and were evaluated for their prognostic value in the post transplantation phase and for their utility to plan adoptive immunotherapy in case of molecular relapse. With respect to chimerism, new and very sensitive methods were introduced, for example, quantitative assessment of genetic polymorphisms by real-time PCR, but also methods here are still highly individualized. Only in CML, where SCT focuses now on poor-risk cases or cases of tyrosine kinase inhibitor failure, follow-up schedules are standardized. Standardization of the different diagnostic techniques and of the intervals in the post transplantation period is urgently needed also in other myeloid malignancies and should be focus of future studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Bloomfield CD, Shuma C, Regal L, Philip PP, Hossfeld DK, Hagemeijer AM et al. Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer 1997; 80: 2191–2198.

    Article  CAS  PubMed  Google Scholar 

  2. Marcucci G, Mrozek K, Bloomfield CD . Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 2005; 12: 68–75.

    Article  CAS  PubMed  Google Scholar 

  3. Swansbury GJ, Lawler SD, Alimena G, Arthur D, Berger R, Van den BH et al. Long-term survival in acute myelogenous leukemia: a second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 1994; 73: 1–7.

    Article  CAS  PubMed  Google Scholar 

  4. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A, Niederwieser D . Results of the EBMT activity survey 2005 on haematopoietic stem cell transplantation: focus on increasing use of unrelated donors. Bone Marrow Transplant 2007; 39: 71–87.

    Article  CAS  PubMed  Google Scholar 

  5. Storb R . Can reduced-intensity allogeneic transplantation cure older adults with AML? Best Pract Res Clin Haematol 2007; 20: 85–90.

    Article  PubMed  Google Scholar 

  6. Kroger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhauser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316–1321.

    Article  CAS  PubMed  Google Scholar 

  7. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092–1099.

    Article  CAS  PubMed  Google Scholar 

  8. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006; 108: 1809–1820.

    Article  CAS  PubMed  Google Scholar 

  9. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  11. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  12. Bornhauser M, Kroger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17.

    Article  PubMed  Google Scholar 

  13. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.

    Article  CAS  PubMed  Google Scholar 

  14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  15. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  PubMed  Google Scholar 

  16. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110: 2991–2995.

    Article  CAS  PubMed  Google Scholar 

  17. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J . Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811–2813.

    Article  CAS  PubMed  Google Scholar 

  18. Grimwade D, Howe K, Langabeer S, Burnett A, Goldstone A, Solomon E . Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse. Leukemia 1996; 10: 61–66.

    CAS  PubMed  Google Scholar 

  19. Leroy H, de BS, Grardel-Duflos N, Darre S, Leleu X, Roumier C et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19: 367–372.

    Article  CAS  PubMed  Google Scholar 

  20. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W . Score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003; 102: 2746–2755.

    Article  CAS  PubMed  Google Scholar 

  21. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266.

    Article  CAS  PubMed  Google Scholar 

  22. Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739.

    Article  CAS  PubMed  Google Scholar 

  23. Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011–4020.

    Article  CAS  PubMed  Google Scholar 

  24. James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W . A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 2005; 11: 546–554.

    Article  CAS  PubMed  Google Scholar 

  25. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370–3373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377–3379.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Tefferi A, Lasho TL, Gilliland G . JAK2 mutations in myeloproliferative disorders. N Engl J Med 2005; 353: 1416–1417.

    Article  CAS  PubMed  Google Scholar 

  28. Bacher U, Badbaran A, Fehse B, Zabelina T, Zander A, Kroger N . Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation (Submitted for publication).

  29. Fehse B, Chukhlovin A, Kuhlcke K, Marinetz O, Vorwig O, Renges H et al. Real-time quantitative Y chromosome-specific PCR (QYCS-PCR) for monitoring hematopoietic chimerism after sex-mismatched allogeneic stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 419–425.

    Article  CAS  PubMed  Google Scholar 

  30. Thiede C, Bornhauser M, Ehninger G . Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation. Acta Haematol 2004; 112: 16–23.

    Article  PubMed  Google Scholar 

  31. Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002; 99: 4618–4625.

    Article  CAS  PubMed  Google Scholar 

  32. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  33. Faderl S, Hochhaus A, Hughes T . Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 657–670.

    Article  PubMed  Google Scholar 

  34. Apperley JF . Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2006, 226–232.

    Article  Google Scholar 

  35. van Marion AM, Thiele J, Kvasnicka HM, van den Tweel JG . Morphology of the bone marrow after stem cell transplantation. Histopathology 2006; 48: 329–342.

    Article  CAS  PubMed  Google Scholar 

  36. Dirnhofer S, Went P, Tichelli A . Diagnostic problems in follow-up bone marrow biopsies of patients treated for acute and chronic leukaemias and MDS. Pathobiology 2007; 74: 115–120.

    Article  PubMed  Google Scholar 

  37. Lioznov M, Ikogho R, Fehse B, Bacher U, Kroger N et al. Factors predicting haematological reconstitution following haemopoietic stem cell transplantation. Bone Marrow Transplant (in press).

  38. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  39. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T . Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia 2004; 18: 120–125.

    Article  CAS  PubMed  Google Scholar 

  40. Fenaux P . Chromosome and molecular abnormalities in myelodysplastic syndromes. Int J Hematol 2001; 73: 429–437.

    Article  CAS  PubMed  Google Scholar 

  41. Sole F, Luno E, Sanzo C, Espinet B, Sanz GF, Cervera J et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Haematologica 2005; 90: 1168–1178.

    CAS  PubMed  Google Scholar 

  42. Bacher U, Haferlach T, Kern W, Hiddemann W, Schnittger S, Schoch C . Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. Ann Hematol 2005; 84: 250–257.

    Article  PubMed  Google Scholar 

  43. Bench AJ, Cross NC, Huntly BJ, Nacheva EP, Green AR . Myeloproliferative disorders. Best Pract Res Clin Haematol 2001; 14: 531–551.

    Article  CAS  PubMed  Google Scholar 

  44. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW . Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001; 113: 763–771.

    Article  CAS  PubMed  Google Scholar 

  45. Bacher U, Kern W, Schoch C, Schnittger S, Hiddemann W, Haferlach T . Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia. Cancer 2006; 106: 839–847.

    Article  PubMed  Google Scholar 

  46. Fuehrer M, Gerusel-Bleck M, Konstantopoulos N, der-Goetze C, Walther JU . FISH analysis of native smears from bone marrow and blood for the monitoring of chimerism and clonal markers after stem cell transplantation in children. Int J Mol Med 2005; 15: 291–297.

    CAS  PubMed  Google Scholar 

  47. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C . Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol 2007; 86: 311–327.

    Article  PubMed  Google Scholar 

  48. Christiansen DH, Andersen MK, Pedersen-Bjergaard J . Mutations of AML1 are common in therapy-related myelodysplasia following therapy with alkylating agents and are significantly associated with deletion or loss of chromosome arm 7q and with subsequent leukemic transformation. Blood 2004; 104: 1474–1481.

    Article  CAS  PubMed  Google Scholar 

  49. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC et al. RUNX1 gene mutation in primary myelodysplastic syndrome—the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol 2007; 139: 405–414.

    Article  CAS  PubMed  Google Scholar 

  50. Shimoni A, Nagler A . Clinical implications of minimal residual disease monitoring for stem cell transplantation after reduced intensity and nonmyeloablative conditioning. Acta Haematol 2004; 112: 93–104.

    Article  PubMed  Google Scholar 

  51. Schlenk RF, Corbacioglu A, Krauter J, Bullinger L, Morgan M, Spaeth D et al. Gene mutations as predictive markers for younger adults with normal karyotype AML. ASH Annual Meeting Abstracts 2006; 108: 6a.

    Google Scholar 

  52. Scholl S, Krause C, Loncarevic IF, Muller R, Kunert C, Wedding U et al. Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia. J Lab Clin Med 2005; 145: 295–304.

    Article  CAS  PubMed  Google Scholar 

  53. Campana D . Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003; 121: 823–838.

    Article  PubMed  Google Scholar 

  54. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004; 104: 3078–3085.

    Article  CAS  PubMed  Google Scholar 

  55. Griesinger F, Piro-Noack M, Kaib N, Falk M, Renziehausen A, Troff C et al. Leukaemia-associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome. Br J Haematol 1999; 105: 241–255.

    Article  CAS  PubMed  Google Scholar 

  56. Kern W, Haferlach C, Haferlach T, Schnittger S . Monitoring of minimal residual disease in acute myeloid leukemia. Cancer 2008; 112: 4–16.

    Article  CAS  PubMed  Google Scholar 

  57. Lion T, Watzinger F . Chimerism analysis following nonmyeloablative stem cell transplantation. Methods Mol Med 2006; 125: 275–295.

    CAS  PubMed  Google Scholar 

  58. Muller-Berat N, Lion T . Chimerism and transplant-related diagnostics. Leukemia 2006; 20: 1358–1360.

    Article  CAS  PubMed  Google Scholar 

  59. Bader P, Klingebiel T, Schaudt A, Theurer-Mainka U, Handgretinger R, Lang P et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079–2086.

    Article  CAS  PubMed  Google Scholar 

  60. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF . Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia. Bone Marrow Transplant 2007; 39: 285–291.

    Article  CAS  PubMed  Google Scholar 

  61. Baron F, Sandmaier BM . Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia 2006; 20: 1690–1700.

    Article  CAS  PubMed  Google Scholar 

  62. Najfeld V, Burnett W, Vlachos A, Scigliano E, Isola L, Fruchtman S . Interphase FISH analysis of sex-mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant 1997; 19: 829–834.

    Article  CAS  PubMed  Google Scholar 

  63. Lapointe C, Forest L, Lussier P, Busque L, Lagace F, Perreault C et al. Sequential analysis of early hematopoietic reconstitution following allogeneic bone marrow transplantation with fluorescence in situ hybridization (FISH). Bone Marrow Transplant 1996; 17: 1143–1148.

    CAS  PubMed  Google Scholar 

  64. Buno I, Nava P, Simon A, Gonzalez-Rivera M, Jimenez JL, Balsalobre P et al. A comparison of fluorescent in situ hybridization and multiplex short tandem repeat polymerase chain reaction for quantifying chimerism after stem cell transplantation. Haematologica 2005; 90: 1373–1379.

    CAS  PubMed  Google Scholar 

  65. Rothberg PG, Gamis AS, Baker D . Use of DNA polymorphisms to monitor engraftment after allogeneic bone marrow transplantation. Clin Lab Med 1997; 17: 109–118.

    Article  CAS  PubMed  Google Scholar 

  66. Thiede C, Bornhauser M, Oelschlagel U, Brendel C, Leo R, Daxberger H et al. Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers. Leukemia 2001; 15: 293–302.

    Article  CAS  PubMed  Google Scholar 

  67. Thiede C . Diagnostic chimerism analysis after allogeneic stem cell transplantation: new methods and markers. Am J Pharmacogenomics 2004; 4: 177–187.

    Article  CAS  PubMed  Google Scholar 

  68. Elmaagacli AH . Real-time PCR for monitoring minimal residual disease and chimerism in patients after allogeneic transplantation. Int J Hematol 2002; 76 (Suppl 2): 204–205.

    Article  PubMed  Google Scholar 

  69. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T . How and when should we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow Transplant 2005; 35: 107–119.

    Article  CAS  PubMed  Google Scholar 

  70. McCann SR, Crampe M, Molloy K, Lawler M . Hemopoietic chimerism following stem cell transplantation. Transfus Apher Sci 2005; 32: 55–61.

    Article  PubMed  Google Scholar 

  71. Kristt D, Stein J, Yaniv I, Klein T . Assessing quantitative chimerism longitudinally: technical considerations, clinical applications and routine feasibility. Bone Marrow Transplant 2007; 39: 255–268.

    Article  CAS  PubMed  Google Scholar 

  72. Matthes-Martin S, Lion T, Haas OA, Frommlet F, Daxberger H, Konig M et al. Lineage-specific chimaerism after stem cell transplantation in children following reduced intensity conditioning: potential predictive value of NK cell chimaerism for late graft rejection. Leukemia 2003; 17: 1934–1942.

    Article  CAS  PubMed  Google Scholar 

  73. Lion T . Detection of impending graft rejection and relapse by lineage-specific chimerism analysis. Methods Mol Med 2007; 134: 197–216.

    Article  CAS  PubMed  Google Scholar 

  74. Lion T, Daxberger H, Dubovsky J, Filipcik P, Fritsch G, Printz D et al. Analysis of chimerism within specific leukocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307–310.

    Article  CAS  PubMed  Google Scholar 

  75. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF . Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica 2007; 92: 1004–1006.

    Article  PubMed  Google Scholar 

  76. Thiede C, Lutterbeck K, Oelschlagel U, Kiehl M, Steudel C, Platzbecker U et al. Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells. Ann Hematol 2002; 81 (Suppl 2): S27–S28.

    PubMed  Google Scholar 

  77. Prinz E, Keil F, Kalhs P, Mitterbauer M, Rabitsch W, Rosenmayr A et al. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation. Ann Hematol 2003; 82: 295–298.

    CAS  PubMed  Google Scholar 

  78. Preisler HD, Priore R, Azarnia N, Barcos M, Raza A, Rakowski I et al. Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol 1986; 63: 625–636.

    Article  CAS  PubMed  Google Scholar 

  79. Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64–70.

    Article  CAS  PubMed  Google Scholar 

  80. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  PubMed  Google Scholar 

  81. Marcucci G, Mrozek K, Ruppert AS, Archer KJ, Pettenati MJ, Heerema NA et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. J Clin Oncol 2004; 22: 2410–2418.

    Article  PubMed  Google Scholar 

  82. El-Rifai W, Ruutu T, Elonen E, Volin L, Knuutila S . Prognostic value of metaphase-fluorescence in situ hybridization in follow-up of patients with acute myeloid leukemia in remission. Blood 1997; 89: 3330–3334.

    CAS  PubMed  Google Scholar 

  83. Gallagher RE, Yeap BY, Bi W, Livak KJ, Beaubier N, Rao S et al. Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003; 101: 2521–2528.

    Article  CAS  PubMed  Google Scholar 

  84. Marcucci G, Caligiuri MA, Dohner H, Archer KJ, Schlenk RF, Dohner K et al. Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with inv(16) acute myeloid leukemia. Leukemia 2001; 15: 1072–1080.

    Article  CAS  PubMed  Google Scholar 

  85. Krauter J, Gorlich K, Ottmann O, Lubbert M, Dohner H, Heit W et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 2003; 21: 4413–4422.

    Article  CAS  PubMed  Google Scholar 

  86. de LA, Pautas C, Thomas X, de BS, Bordessoule D, Tilly H et al. Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia. Bone Marrow Transplant 2005; 35: 767–773.

    Article  Google Scholar 

  87. Grimwade D, Jamal R, Goulden N, Kempski H, Mastrangelo S, Veys P . Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. Br J Haematol 1998; 103: 559–562.

    Article  CAS  PubMed  Google Scholar 

  88. Yanada M, Matsuo K, Emi N, Naoe T . Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005; 103: 1652–1658.

    Article  PubMed  Google Scholar 

  89. Elmaagacli AH, Beelen DW, Kroll M, Trzensky S, Stein C, Schaefer UW . Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998; 21: 159–166.

    Article  CAS  PubMed  Google Scholar 

  90. Miyamoto T, Nagafuji K, Akashi K, Harada M, Kyo T, Akashi T et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87: 4789–4796.

    CAS  PubMed  Google Scholar 

  91. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.

    Article  CAS  PubMed  Google Scholar 

  92. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.

    Article  CAS  PubMed  Google Scholar 

  93. Cloos J, Goemans BF, Hess CJ, van Oostveen JW, Waisfisz Q, Corthals S et al. Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples. Leukemia 2006; 20: 1217–1220.

    Article  CAS  PubMed  Google Scholar 

  94. Schnittger S, Schoch C, Kern W, Hiddemann W, Haferlach T . FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia. Acta Haematol 2004; 112: 68–78.

    Article  CAS  PubMed  Google Scholar 

  95. Elmaagacli AH . Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders. Methods Mol Med 2007; 134: 161–178.

    Article  CAS  PubMed  Google Scholar 

  96. Scholl S, Loncarevic IF, Krause C, Kunert C, Clement JH, Hoffken K . Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia. Leuk Res 2005; 29: 849–853.

    Article  CAS  PubMed  Google Scholar 

  97. van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ . Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013–1034.

    Article  CAS  PubMed  Google Scholar 

  98. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746.

    Article  CAS  PubMed  Google Scholar 

  99. Verhaak RG, Goudswaard CS, van PW, Bijl MA, Sanders MA, Hugens W et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754.

    Article  CAS  PubMed  Google Scholar 

  100. Falini B, Bolli N, Shan J, Martelli MP, Liso A, Pucciarini A et al. Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. Blood 2006; 107: 4514–4523.

    Article  CAS  PubMed  Google Scholar 

  101. Gorello P, Cazzaniga G, Alberti F, Dell'Oro MG, Gottardi E, Specchia G et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006; 20: 1103–1108.

    Article  CAS  PubMed  Google Scholar 

  102. Chou WC, Tang JL, Wu SJ, Tsay W, Yao M, Huang SY et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007; 21: 998–1004.

    Article  CAS  PubMed  Google Scholar 

  103. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005; 19: 1416–1423.

    Article  CAS  PubMed  Google Scholar 

  104. Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003; 101: 1698–1704.

    Article  CAS  PubMed  Google Scholar 

  105. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S et al. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003; 123: 243–252.

    Article  PubMed  Google Scholar 

  106. Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W . Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004; 62: 25–38.

    Article  PubMed  Google Scholar 

  107. Ito S, Ishida Y, Murai K, Kuriya S . Flow cytometric analysis of aberrant antigen expression of blasts using CD45 blast gating for minimal residual disease in acute leukemia and high-risk myelodysplastic syndrome. Leuk Res 2001; 25: 205–211.

    Article  CAS  PubMed  Google Scholar 

  108. Nagler A, Condiotti R, Rabinowitz R, Schlesinger M, Nguyen M, Terstappen LW . Detection of minimal residual disease (MRD) after bone marrow transplantation (BMT) by multi-parameter flow cytometry (MPFC). Med Oncol 1999; 16: 177–187.

    Article  CAS  PubMed  Google Scholar 

  109. Wells DA, Sale GE, Shulman HM, Myerson D, Bryant EM, Gooley T et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 1998; 110: 84–94.

    Article  CAS  PubMed  Google Scholar 

  110. Perez-Simon JA, Caballero D, ez-Campelo M, Lopez-Perez R, Mateos G, Canizo C et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. Leukemia 2002; 16: 1423–1431.

    Article  CAS  PubMed  Google Scholar 

  111. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.

    Article  CAS  PubMed  Google Scholar 

  112. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T . Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia 2005; 19: 1345–1349.

    Article  CAS  PubMed  Google Scholar 

  113. Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004; 18: 466–475.

    Article  CAS  PubMed  Google Scholar 

  114. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S . A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007; 92: 744–752.

    Article  CAS  PubMed  Google Scholar 

  115. Bader P, Niemeyer C, Weber G, Coliva T, Rossi V, Kreyenberg H et al. WT1 gene expression: useful marker for minimal residual disease in childhood myelodysplastic syndromes and juvenile myelo-monocytic leukemia? Eur J Haematol 2004; 73: 25–28.

    Article  CAS  PubMed  Google Scholar 

  116. Tamaki H, Ogawa H, Ohyashiki K, Ohyashiki JH, Iwama H, Inoue K et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999; 13: 393–399.

    Article  CAS  PubMed  Google Scholar 

  117. Tamura K, Kanazawa T, Suzuki M, Koitabashi M, Ogawa C, Morikawa A . Successful rapid discontinuation of immunosuppressive therapy at molecular relapse after allogeneic bone marrow transplantation in a pediatric patient with myelodysplastic syndrome. Am J Hematol 2006; 81: 139–141.

    Article  PubMed  Google Scholar 

  118. Wells DA, Benesch M, Loken MR, Vallejo C, Myerson D, Leisenring WM et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102: 394–403.

    Article  CAS  PubMed  Google Scholar 

  119. Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002; 16: 53–59.

    Article  CAS  PubMed  Google Scholar 

  120. Hochhaus A, Lin F, Reiter A, Skladny H, Hehlmann R, Goldman JM et al. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha. Bone Marrow Transplant 1996; 17 (Suppl 3): S41–S44.

    PubMed  Google Scholar 

  121. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87: 1549–1555.

    CAS  PubMed  Google Scholar 

  122. Kurzrock R, Gutterman JU, Talpaz M . The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319: 990–998.

    Article  CAS  PubMed  Google Scholar 

  123. Melo JV . The molecular biology of chronic myeloid leukaemia. Leukemia 1996; 10: 751–756.

    CAS  PubMed  Google Scholar 

  124. Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003; 70: 1–10.

    Article  CAS  PubMed  Google Scholar 

  125. Kim MH, Stewart J, Devlin C, Kim YT, Boyd E, Connor M . The application of comparative genomic hybridization as an additional tool in the chromosome analysis of acute myeloid leukemia and myelodysplastic syndromes. Cancer Genet Cytogenet 2001; 126: 26–33.

    Article  CAS  PubMed  Google Scholar 

  126. Martinelli G, Iacobucci I, Soverini S, Cilloni D, Saglio G, Pane F et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006; 24: 196–204.

    Article  CAS  PubMed  Google Scholar 

  127. DeAngelo DJ, Hochberg EP, Alyea EP, Longtine J, Lee S, Galinsky I et al. Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res 2004; 10: 5065–5071.

    Article  CAS  PubMed  Google Scholar 

  128. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ . A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91: 663–666.

    CAS  PubMed  Google Scholar 

  129. Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R et al. BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning. Leukemia 2004; 18: 1468–1475.

    Article  CAS  PubMed  Google Scholar 

  130. Asnafi V, Rubio MT, Delabesse E, Villar E, Davi F, Damaj G et al. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2006; 20: 793–799.

    Article  CAS  PubMed  Google Scholar 

  131. Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99: 3861–3862.

    Article  CAS  PubMed  Google Scholar 

  132. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–3475.

    Article  CAS  PubMed  Google Scholar 

  133. Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101: 3794–3800.

    Article  CAS  PubMed  Google Scholar 

  134. Gruber FX, Lamark T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005; 19: 2159–2165.

    Article  CAS  PubMed  Google Scholar 

  135. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007; 110: 4005–4011.

    Article  CAS  PubMed  Google Scholar 

  136. Ernst T, Erben P, Muller MC, Paschka P, Schenk T, Hoffmann J et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008; 93: 186–192.

    Article  CAS  PubMed  Google Scholar 

  137. Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006; 108: 1497–1503.

    Article  CAS  PubMed  Google Scholar 

  138. Kroger N, Thiele J, Zander A, Schwerdtfeger R, Kobbe G, Bornhauser M et al. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Exp Hematol 2007; 35: 1719–1722.

    Article  CAS  PubMed  Google Scholar 

  139. Steensma DP . JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 2006; 8: 397–411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Fiorini A, Reddiconto G, Farina G, Marietti S, Palladino M, Chiusolo P et al. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. Leukemia 2006; 20: 2198–2199.

    Article  CAS  PubMed  Google Scholar 

  141. Ruiz-Arguelles GJ, Garces-Eisele J, Reyes-Nunez V, Ruiz-Delgado GJ, Rosillo C, Camoriano JK . Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia. Am J Hematol 2007; 82: 400–402.

    Article  CAS  PubMed  Google Scholar 

  142. Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N et al. A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD). Leuk Res 2008; 32: 421–427.

    Article  CAS  PubMed  Google Scholar 

  143. Steckel NK, Koldehoff M, Ditschkowski M, Beelen DW, Elmaagacli AH . Use of the activating gene mutation of the tyrosine kinase (Val617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 2007; 83: 1518–1520.

    Article  CAS  PubMed  Google Scholar 

  144. Levine RL, Wernig G . Role of JAK-STAT Signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program 2006, 233–239.

    Article  Google Scholar 

  145. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.

    Article  CAS  PubMed  Google Scholar 

  146. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006; 3: e270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Lo CF, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG . Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999; 94: 12–22.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    U Bacher, A R Zander, B Fehse & N Kröger

  2. MLL Munich Leukemia Laboratory, Munich, Germany

    T Haferlach & S Schnittger

  3. Department of Experimental Pediatric Oncology and Hematology, Hospital of the Johann Wolfgang Goethe-University, Frankfurt am Main, Germany

    B Fehse

Authors
  1. U Bacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A R Zander
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Haferlach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Schnittger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Fehse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Kröger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U Bacher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bacher, U., Zander, A., Haferlach, T. et al. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 42, 145–157 (2008). https://doi.org/10.1038/bmt.2008.185

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.185

Keywords

This article is cited by

Search

Advanced search

Quick links